Age-related macular degeneration (VEGF)

Age-related macular degeneration (VEGF)

  • April 2016 •
  • 190 pages •
  • Report ID: 4035422 •
  • Format: PDF
Eylea overtakes Lucentis in 2015 to become the highest selling anti-VEGF treatment for wet AMD, just four years after its first launch.

This report addresses the following questions:

- How do treatment practices vary in the US and EU between the three major VEGF inhibitors?
- Why has Eylea been able to quickly position itself as a standard-of-care and overtake Lucentis?
- What factors will contribute to the expansion of the wet AMD market value over the next ten years?
- What impact will future biosimilar VEGF therapies have on the branded market?
- How should pipeline therapies position themselves for maximum commercial success?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.